BioWorld

March 23, 2004

View Archived Issues

Raptiva Preliminary Data Poor In Psoriatic Arthritis Phase II

Poor preliminary Phase II results of Raptiva in psoriatic arthritis patients caused slight dips in Genentech Inc. and XOMA Ltd.'s value. (BioWorld Today) Read More

Recently Formed By Merger, PainCeptor Nets C$23 Million

Read More

Humble Fruit Fly Yields Still More Disease Clues In TLRs

Read More

Other News To Note

Read More

Appointments And Advancements

Read More